Clinical trials: sponsored by Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
The purpose of this study is to evaluate efficacy and safety of SHR-3167 versus Insulin glargine in insulin-naive type 2 diabetes inadequately controlled on non-insulin anti-diabetic drugs.
- Trial name
- NCT07920939
- Testing
- SHR-3167 Injection, Insulin glargine (IGlar)
- Where
- 2 sites in China
- Volunteers
- 450 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Gestational Trophoblastic Neoplasia
Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia
The purpose of this study is to evaluate the efficacy and safety of camrelizumab and apatinib as combination therapy in patients with ultra high-risk (Cohort A) and high-risk chemo-refractory or relapsed (Cohort B) gestational…
- Trial name
- NCT05139095
- Testing
- Camrelizumab plus apatinib CohortA, Camrelizumab plus apatinib Cohort B
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Peking Union Medical College Hospital
Diabetes Mellitus, Type 2
A Study Comparing SHR-3167 With Insulin Degludec in Adults With Type 2 Diabetes Currently Treated With Basal Insulin
The purpose of this study is to evaluate efficacy and safety of once-weekly SHR-3167 and once-daily Insulin Degludec in participants with Type 2 diabetes that has been treated with basal insulin.
- Trial name
- NCT07913061
- Testing
- SHR-3167, insulin degludec
- Where
- 2 sites in China
- Volunteers
- 680 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Early Breast Cancer
Nab-paclitaxel in Combination With Pyrotinib in Postoperative Adjuvant Therapy for HER2-positive Breast Cancer
This is a multicenter, open-label, single-arm, prospective, phase II study. conducted to evaluate the efficacy, safety and tolerability of nab-paclitaxel plus pyrotinib in patients with lymph node-negative and tumor size ≤3 cm…
- Trial name
- NCT04659499
- Testing
- Nab-paclitaxel in combination with pyrotinib
- Where
- China
- Volunteers
- 263 people
- Sponsor
- Peking Union Medical College Hospital
Preoperative Sedation
A Trial of Dexmedetomidine Hydrochloride Nasal Spray in Preoperative Sedation of Adults
The study is being conducted to evaluate the efficacy and safety of dexmedetomidine hydrochloride nasal spray for preoperative sedation in adults.
- Trial name
- NCT04383418
- Testing
- dexmedetomidine hydrochloride nasal spray, dexmedetomidine hydrochloride nasal spray blank preparation
- Where
- China
- Volunteers
- 309 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer
Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer
This is a multi-center, open-lable, prospective, randomized phase III clinical trial to further validate the efficacy and safety of neoadjuvant pyrotinib combined with chemotherapy in HR-positive/HER2-low (IHC 2+/FISH-negative)…
- Conditions
- Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer, HER2 Low Breast Carcinoma, Early-stage Breast Cancer
- Trial name
- NCT06144944
- Testing
- Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel, Epirubicin or doxorubicin, cyclophosphamide, paclitaxel
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Locally Advanced, Recurrent or Metastatic ESCC Patients Who Have Failed Prior PD-1/PD-L1 Inhibitors Combined With Platinum-based Chemotherapy
FH-006 Versus Investigator's Choice of Chemotherapy in Patients With Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma Who Have Failed Prior PD-1/PD-L1 Inhibitor Combined With Platinum-Based Chemotherapy.
The study compares the overall survival (OS) of FH-006 and the second-line chemotherapy selected by the investigators for treating esophageal squamous cell carcinoma patients.
- Trial name
- NCT07790380
- Testing
- FH-006, Paclitaxel, Docetaxel, Irinotecan
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Breast Cancer
A Phase III Clinical Study of HRS-6209 Plus Letrozole as First-line Therapy in Patients With Advanced or Metastatic Breast Cancer
The purpose of this study is to investigate the efficacy and safety of HRS-6209 in combination with letrozole compared with dalpciclib or palbociclib in combination with aromatase inhibitor in patients with advanced or metastatic…
- Trial name
- NCT07894328
- Testing
- HRS-6209 + Letrozole, Dalpciclib/Palbociclib + Letrozole/Anastrozole
- Where
- China
- Volunteers
- 1,050 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Pancreatic Cancer
An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors
This is a Phase IB/II clinical trial designed to evaluate HRS-7172 in combination with antitumor drugs in participants with advanced pancreatic cancer harboring RAS mutations or amplifications.
- Trial name
- NCT07806058
- Testing
- HRS-7172 + AG + SHR-1316, HRS-7172 + AG + SHR-1316;, HRS-7172 + AG;
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting
HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer
This study investigates the first-line treatment of advanced pancreatic cancer with KRAS G12D mutation. Patients were randomized 1:1 to receive either the experimental regimen HRS-4642 plus AG or the control regimen AG alone.
- Trial name
- NCT07232875
- Testing
- HRS-4642 + AG
- Where
- China
- Volunteers
- 588 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP)
A Trial of HRS-8427 in the Treatment of Adults With Bacterial Pneumonia
The purpose of this study is to evaluate the efficacy and safety of HRS -8427 in patients with HABP/VABP.
- Trial name
- NCT06841731
- Testing
- HRS-8427, Meropenem
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Advanced Unresectable or Metastatic Breast Cancer, Advanced Solid Tumors
A Trial of HRS-6209 in Combination With Other Antitumor Therapies in Breast Cancer Patients or HRS-9813 as Monotherapy in Patients With Advanced Solid Tumors
The study is being conducted to evaluate the safety, PK and efficacy of HRS-6209 in Combination with Fulvestrant, Letrozole, HRS-8080, HRS-1358 ,or HRS-9813 and HRS-8080，or letrozole and trastuzumab, with or without pertuzumab…
- Trial name
- NCT06555068
- Testing
- HRS-6209 in Combination with Fulvestrant, HRS-6209 in Combination with HRS-1358, HRS-6209 in Combination with Letrozole
- Where
- China
- Volunteers
- 528 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Breast Neoplasms
Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)
Based on different HR status, we explored the efficacy and safety of Pyrotinib and Dalpiciclib Isethionate Tablets based combination regimen in the first-line treatment of HER2 + MBC.
- Trial name
- NCT05328440
- Testing
- Pyrotinib Maleate, Dalpiciclib Isethionate Tablets, Inetetamab
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Henan Cancer Hospital
Sarcomatoid Carcinoma of Lung
Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma
This is a single arm, multi-center clinical trial. Target population is patients with Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma，aiming to evaluate the efficacy and safety of the combination therapy of Camrelizumab…
- Trial name
- CAPSTONE (NCT04888429)
- Testing
- Camrelizumab, Famitinib
- Where
- 8 sites in China
- Volunteers
- 17 people
- Sponsor
- Qian Chu
Hepatocellular Carcinoma
Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC
This study intends to prospectively enroll CNLC stage IIIb HCC cases with extrahepatic metastasis and intrahepatic lesions that are expected to be radical resected in several domestic clinical centers, and observe the OS and ORR…
- Trial name
- NCT05062837
- Testing
- Hepatectomy Combined With Camrelizumab and Apatinib
- Where
- China
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Guangxi Medical University
Patients With Chemotherapy-Induced Thrombocytopenia
A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia (ExCIT)
The ExCIT study is being conducted to evaluate the efficacy, and safety of of Hetrombopag Olamine Tablets Vs Placebo in Patients with Chemotherapy-Induced Thrombocytopenia.
- Trial name
- NCT07286032
- Testing
- Hetrombopag Olamine
- Where
- 51 sites in United States, Bulgaria and 9 more
- Volunteers
- 150 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)
A Trial of HRS-8427 in the Treatment of Adults With Complicated Urinary Tract Infection, Including Acute Pyelonephritis
The purpose of this study is to evaluate the efficacy and safety of HRS-8427 in patients with complicated urinary tract infection, including acute pyelonephritis.
- Trial name
- NCT06569056
- Testing
- HRS-8427, Imipenem and Cilastatin Sodium
- Where
- China
- Volunteers
- 579 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Local Analgesia Via Infiltration
A Study of Bupivacaine Liposome Injection in Local Analgesia of Pediatric Patients
The study is being conducted to evaluate the safety and efficacy of bupivacaine liposome injection for local infiltration analgesia in pediatric orthopedic surgery in the real world.
- Trial name
- NCT06344091
- Testing
- Bupivacaine Liposome Injection
- Where
- China
- Volunteers
- 232 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Prostate Cancer
A Clinical Study of HRS-7525 Tablets in Patients With Advanced Prostate Cancer
The purpose of this study is to evaluate the safety and tolerability of HRS-7525 in participants with Advanced Prostate Cancer, and to determine the dose limiting toxicity (DLT), the maximum tolerated dose (MTD, if possible), and…
- Trial name
- NCT07711184
- Testing
- HRS-7525 tablets
- Where
- 7 sites in Australia, China
- Volunteers
- 320 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Malignant Solid Tumor
A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors
This study aims to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of FH-006 in subjects with advanced malignant solid tumors, and determine the preliminary efficacy.
- Trial name
- NCT07136142
- Testing
- FH-006 for Injection, SHR-1316 Injection, Paclitaxel for Injection (Albumin-Bound)
- Where
- 2 sites in China
- Volunteers
- 150 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.